583 results about "Sequence identity" patented technology

There is provided a fluorinase variant thereof having at least 70% sequence identity to a sequence MSDLGX6TDDSVAQCKGLMLSICPX24VX26IX28DX30CHX33MTPX37DVVEGARYIVDLPR X52FPEGTVFATTTYPATGTX70X71RSVAX76RX78KX80AALGGARGQX90AGSGX95GX97E RAEGX103YIYIAPNNGLLTX116VIEEHGYX124EAYEVSX131TX133VIPX137X138PEPTFYSR EMVAIPSAHLAAGFPLX163X164VGRX168LX170DX172EIVRFEX179X180KX182X183X184VX186G X188X189LX191GX193X194X195X196X197DHPFGNX204WTNX208HRTDLEKAGIX219YX221TX223X 224KX226VX228DGVLX233FX235LPLX239PTFADAX246X247X248GX250PVX253YX255NSRGYLX2 62X263ARNAAX269LAYPYNLX277AGX280SVX283VTX286A (SEQ ID NO: 1), wherein X is a natural amino acid, and wherein the variant comprises one or more mutations at a site selected from the group consisting of an ion-egress site, a S-Adenosyl-L-Methionine (SAM) binding site, an ion-binding site (IBS), and a conserved site. Also disclosed are polynucleotides encoding the variants, vectors comprising the polynucleotides encoding the variants, and host cells comprising the vectors thereof. Also disclosed are Methods for producing the variants, methods of catalyzing the fluorination of a compound, uses of the fluorinase variants, and methods of treatment using the fluorinase variants thereof.

The invention provides formaldehyde lyase as well as a mutant and application thereof. The amino acid sequence of the formaldehyde lyase mutant is shown as SEQ ID NO.1, SEQ ID NO.4 or SEQ ID NO.6 and contains at least one of the following sites: S26, W86, N87 or Y87, L109 or M109, L110, H281, Q282 or E282 and A460, and the amino acid sequence is subjected to amino acid mutation and has a formaldehyde lyase activity function. The amino acid sequences of the formaldehyde lyase and the mutants of the formaldehyde lyase have at least 99% of sequence identity with SEQ ID NO.1-7. The formaldehyde lyase and the mutant thereof can catalyze formaldehyde to synthesize 1, 3-dihydroxyacetone, and a new way for converting formaldehyde into 1, 3-dihydroxyacetone is provided.

A deaminase, a fusion protein and the use thereof. The deaminase contains an amino acid sequence having at least 50% sequence identity to any one of SEQ ID NOs: 1-6, 39-164 and 297-312, and the deaminase can deaminize at least one nucleotide in a target polynucleotide. The deaminase can be fused with a nucleic acid-binding polypeptide to obtain various base editors for the sequence-specific base conversion of the target polynucleotide. The performance of the editors can be further improved by means of fusing one or two UGIs, fusing a Gam protein and other strategies.

The invention relates to the technical field of gene isolation and plant improvement, in particular to a late blight resistance gene, a biological material and application. The Rpi-card1 nucleic acid molecule provided by the invention comprises a nucleotide sequence as shown in any one of SEQ ID NO: 1-4; a nucleotide sequence encoding the amino acid sequence represented by SEQ ID NO: 5 or 6; the nucleotide sequence has at least 75% sequence identity with the nucleotide sequence. The invention provides an important gene resource for potato late blight resistance breeding, overcomes the problem of disease resistance loss of potato varieties, and provides a new guarantee for lasting disease resistance of potatoes.

The present invention provides an anti-CCR9 antibody or antigen binding fragment thereof comprising a variable light chain comprising SEQ ID NO:1 or a variant thereof having at least 95% sequence identity to SEQ ID NO:1, wherein the variable light chain comprises a CDR-L1 comprising the amino acid sequence RSSQSLXHSNGXTFLH (SEQ ID NO: 2), a CDR-L2 comprising the amino acid sequence KVSNRFS (SEQ ID NO: 3) and a CDR-L3 comprising the amino acid sequence SQTTHXPWT (SEQ ID NO: 4), wherein X can be any amino acid. Also provided is the anti-CCR9 antibody or antigen binding fragment thereof for use in the treatment or prevention of a disease, as well as methods of diagnosis and antibody drug conjugates.

The invention relates to the field of biological medicine, and provides a monoclonal antibody for recognizing Profilin-1 and application of the monoclonal antibody. The antibody provided by the invention is selected from at least one of the following: (1) light chain CDR sequences as shown in SEQ ID NO: 5, 6 and 7, and heavy chain CDR sequences as shown in SEQ ID NO: 8, 9 and 10; (2) light chain CDR sequences as shown in SEQ ID NO: 11, 12 and 13, and heavy chain CDR sequences as shown in SEQ ID NO: 14, 15 and 16; or an amino acid sequence having at least 80% sequence identity compared with (1) or (2). In addition, the invention also discloses an enzyme immunoassay kit prepared by using the antibody, and the enzyme immunoassay kit has relatively high sensitivity and specificity.

The invention relates to a recombinant I-type humanized collagen with crosslinking property as well as a preparation method and application thereof, and belongs to the technical field of recombinant proteins. The invention relates to recombinant I-type humanized collagen with crosslinking property. The amino acid sequence of the recombinant I-type humanized collagen comprises an amino acid sequence as shown in SEQ ID No.1 or a derivative amino acid sequence with the sequence identity of more than 90% with the sequence as shown in SEQ ID No.1; the recombinant I-type humanized collagen has a triple helix structure. A complete triple helix structure can be efficiently expressed, and the hydrogel has efficient cross-linking capability, so that the hydrogel can be efficiently and stably formed through cross-linking.

The invention belongs to the technical field of biological medicine, and particularly relates to a T cell receptor capable of recognizing KRAS G12V antigen oligopeptide, a compound, a pharmaceutical composition and application. The T cell receptor can be used for recognizing a KRAS G12V-HLA-A * 11: 01 compound with high affinity; the T cell receptor is an alpha-beta heterodimer consisting of an alpha chain and a beta chain; the amino acid sequence of the alpha chain is as shown in SEQ ID NO.10, or an amino acid sequence with at least 90% of sequence identity with the alpha chain; the amino acid sequence of the beta chain is as shown in SEQ ID NO.14, or has an amino acid sequence with at least more than 90% of sequence identity with the beta chain. The T cell receptor provided by the invention can be used for preparing medicines for treating tumors or other immune diseases.

There is provided an interleukin-21 (IL-21) variant, wherein in comparison to wild-type IL-21 that comprises an amino acid sequence according to SEQ ID NO: 6 or an amino acid sequence comprising at least 70% sequence identity to SEQ ID NO: 6, the IL-21 variant comprises an amino acid modification at one or more of the following amino acid positions: 29, 33, 36 and / or 71.

There is disclosed a mutant, non-naturally occurring or transgenic tobacco plant or part thereof having modulated expression or activity of lysine ketoglutarate reductase (LKR) comprising, consisting of, or consisting essentially of: (i) a polynucleotide, the present invention relates to a protein comprising, consisting or consisting essentially of a sequence having at least 88% sequence identity to SEQ ID NO: 1 (NtLKR-S) and / or a sequence having at least 86% sequence identity to SEQ ID NO: 3 (NtLKR-T); (ii) a polypeptide encoded by the polynucleotide set forth in (i); (iii) a polypeptide comprising, consisting or consisting essentially of a sequence having at least 89% sequence identity to SEQ ID NO: 2 (NtLKR-S) and / or a sequence having at least 88% sequence identity to SEQ ID NO: 4 (NtLKR-T); or (iv) a construct, vector or expression vector comprising the isolated polynucleotide set forth in (i) wherein the plant or part thereof comprises at least one modification as compared to a control plant or part thereof wherein the expression of the polynucleotide or the activity of the polypeptide is not modified, the at least one modification is capable of modulating: (a) expression of the polynucleotide in the plant or part thereof; or (b) the activity of the polypeptide in the plant or part thereof.

Described are lipopeptides that inhibit coronavirus fusion to a host cell. Thus a therapeutic for treating or preventing the common cold is described along with methods of inhibiting and / or treating an alphacoronavirus infection. The lipopeptides comprise a peptide unit comprising an amino acid sequence having a high degree of sequence identity to a sequence from the C-terminal heptad repeat of a betacoronavirus S protein, such as that of SARS-CoV-2.

The invention relates to a recombinant elastin and a preparation method thereof as well as a recombinant elastin raw material and application thereof, and belongs to the technical field of recombinant proteins. The amino acid sequence of the recombinant elastin is an amino acid sequence as shown in SEQ ID No.1 or a derivative amino acid sequence of which the sequence identity with the SEQ ID No.1 is more than 90%. The protein is high in expression level, high in purity and relatively high in biological activity, and has the effects of supplementing skin collagen, resisting aging and repairing skin barriers.

Provided is a heat-resistant D-allulose-3-epimerase. A polypeptide shown in any one of the following (1) to (3):(1) a polypeptide consisting of an amino acid sequence having one or two or more amino acid substitutions selected from the group consisting of A56E, N57H, R58G and F111W in SEQ ID NO:1;(2) a polypeptide consisting of the amino acid sequence having substitution, addition, insertion or deletion of one or several amino acid residues in the amino acid sequence described in (1) above, having D-allulose-3-epimerase activity and retaining one or two or more amino acid substitutions selected from the group consisting of A56E, N57H, R58G, and F111W; and(3) a polypeptide having a 90% or more sequence identity to the amino acid sequence described in (1) above, having D-allulose-3-epimerase activity and retaining one or two or more amino acid substitutions selected from the group consisting of A56E, N57H, R58G, and F111W.

The present invention pertains to protein oligomers for active immunization. Specifically, the invention relates to protein oligomers comprising at least a first monomer and a second 5 monomer, said at least first and second monomer comprising, in N- to C-terminal order, at least one first RBD, an immunoglobulin Fc (Ig Fc), and at least one second RBD, wherein a) Ig Fc has enhanced affinity for the neonatal Fc receptor (FcRn) at mucosal pH, compared to wildtype Ig Fc; and b) RBD is a receptor binding domain from or derived from SARS-CoV-2 spike protein, wherein the receptor binding domain comprises the amino acid sequence of SEQ ID NO. 13, or a fragment thereof, or an amino acid sequence having at least 80%, 85%, 90%, or 95% sequence identity to SEQ ID NO. 13. The invention further relates to a vaccine comprising said protein oligomer, preferably for use in active immunization and / or booster vaccination in a subject.

A Delta-Like Ligand 3 (DLL3) binding peptide having a binding specificity to human DLL3, comprising an amino acid sequence having at least 98%, 95%, or 92% of sequence identity to SEQ ID NO: 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 37, 38, 39, 40, 41, 42, 43, 44, 45, or 46.

The present disclosure provides adenosine deaminase, fusion proteins, base editor systems and uses, and specifically provides an adenosine deaminase polypeptide having an amino acid sequence having at least about 70%, 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or at least about 99% sequence identity to SEQ ID NO: 13. Also provided are novel nucleic acid modified enzymes having improved efficiency, compositions of base editors comprising the same, and methods and uses for editing target sequences using these adenosine deaminase variants.

The present invention addresses the problem of providing: a reagent for measuring an anti-gastric wall cell antibody and a kit for measuring an anti-gastric wall cell antibody, in order to detect an anti-gastric wall cell antibody; and a method for measuring an anti-gastric wall cell antibody in a sample. The present invention provides: a reagent for measuring an anti-gastric wall cell antibody, the reagent containing a protein which has an N-linked sugar chain and which is any one of (1) to (3); and (1) a protein containing at least the amino acid sequence of SEQ ID NO: 1; Provided is: (2) a protein containing at least an amino acid sequence which has 90% or more sequence identity with SEQ ID NO: 1, and containing an amino acid sequence that is capable of binding to the anti-gastric wall cell antibody; or (3) a protein containing at least the amino acid sequence of SEQ ID NO: 1 with one to several amino acids substituted, deleted, added and / or inserted, and containing an amino acid sequence that is capable of binding to the anti-gastric wall cell antibody.

The invention relates to peptides comprising or consisting of an amino acid sequence of 5 to 50 amino acids which has, in N- to C-terminus orientation, the amino acid sequence X5X6X7X8X9, where each of the five residues X represents an amino acid of a particular group, and / or the amino acid sequence has at least 85% sequence identity to one of the amino acid sequences mentioned in SEQ ID NOs: 1 - 17.

The invention provides a circular RNA circ0004801 and an application of the circular RNA circ0004801 in treatment of an Alzheimer's disease. The nucleotide sequence of the circular RNA circ0004801 is as shown in SEQ ID NO: 1 (Sequence Identity Number 1). The expression of the circular RNA circ0004801 in the hippocampal tissue of the AD mouse is obviously up-regulated, and the circular RNA circ0004801 is used as a'sponge 'of miR-7688-5p and plays a role by adjusting the TTBK1 expression and tau phosphorylation level. By knocking down the circular RNA circ0004801, the spatial learning and memory of a 3 * Tg mouse can be obviously improved, and the tau protein phosphorylation level of a hippocampus region and the NFTs density of a hippocampus DG region can be obviously reduced. Therefore, the circular RNA circ0004801 and the miR-7688-5p can be used as new targets for treating the AD (Alzheimer's disease). According to the invention, it is found for the first time that circular RNA circ0004801 regulates TTBK1 through a ceRNA mechanism, so that excessive phosphorylation of tau is driven, and a new molecular target is provided for AD early intervention treatment based on circRNA and miRNA.

To provide a technique for reducing the count of bacteria involved in mucin decomposition within the intestine, wherein the present invention allows inhibition of growth of intestinal microbes such as Ruminococcus gnavus, which can be involved in mucin degradation; and thus, it becomes possible to reduce mucin degradation within the intestine, thereby preserving the intestinal barrier function, and contributing to the maintenance or enhancement of host health.SOLUTION: Provided is an agent that comprises agaro-oligosaccharides as an active ingredient to inhibit the growth of intestinal bacteria having, in genomic DNA, a NanA gene composed of a DNA sequence having at least 45.6% sequence identity to Sequence No. 1 (NanA gene of Ruminococcus gnavus).SELECTED DRAWING: Figure 1

The invention relates to the technical field of biology, and particularly discloses polypeptide, recombinant XIX type humanized collagen and application of the recombinant XIX type humanized collagen. The amino acid sequence of the polypeptide comprises n repetitive units; the repetitive unit comprises any one of the following amino acid sequences or variant sequences thereof: (1) an amino acid sequence as shown in any one of SEQ ID NO.1-2; (2) an amino acid sequence having at least 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% sequence identity with the amino acid sequence as shown in any one of SEQ ID NO.1-2; (3) a variant sequence obtained by performing mutation of one or more amino acid residues on the amino acid sequence as shown in any one of SEQ ID NO.1-2; wherein n is an integer greater than or equal to 1. The polypeptide provided by the invention has a collagen triple helix structure, has good cell adhesion activity, can carry out functions of human collagen, is free of immunological rejection and anaphylactic reaction, and can be used in various fields of cartilage repair, biological dressing, tissue filling and the like.

Disclosed herein are nucleic acid compositions and methods of use. The nucleic acid compositions may have a therapeutic nucleic acid sequence operably linked to a nuclear targeting sequence that increases expression of the therapeutic nucleic acid in a cell by at least 1.25 fold; at least 80% sequence identity to SEQ ID NO: 6; or a first regulatory element comprising a promoter sequence operably linked to a hemoglobin subunit gamma intron (hBGi) sequence, and a second regulatory element comprising a woodchuck hepatitis posttranscriptional regulatory element (WPRE) sequence. The nucleic acid compositions with these features may enhance therapeutic nucleic acid transfection and expression. Also disclosed herein are transgenes optimized for gene therapy applications, including novel FVIII transgene sequences, in which the B domain may be non-naturally occurring the A1 and / or A3 domain may include at least one amino acid substitution.

The invention relates to a nucleic acid molecule for preparing indigoidine, an expression vector and a recombinant engineering strain. The nucleic acid molecule comprises a sequence as shown in SEQ ID NO.2 or a nucleotide sequence which has at least 98% sequence identity with the SEQ ID NO.2. According to the present invention, the Wlpl protein encoded by the nucleic acid molecule is derived from Williamsiapylosphaerae bacteria, the amino acid sequence of the Wlpl protein is represented by SEQ ID NO.1, the protein has excellent 4 '-phosphoric acid pantetheine transferase catalytic activity, and when the Wlpl protein is used for catalyzing the synthesis process of glutamine to synthesize the indigoidine, the yield of the indigoidine can achieve 14.26 g / L, such that the indigoidine yield is substantially improved, and the good industrialization prospect is provided;

A glycosylated p75NTR neurotrophin binding protein (NBP)-Fc fusion protein, comprising: a p75NTR(NBP) portion, having at least 85% sequence identity with Seq ID No. 3; and an immunoglobulin Fc portion. wherein, the p75NTR(NBP) and Fc portions are connected via a linker, the linker comprises a peptide of formula Gx, where x is 1, 2, 3, 4, 5 or 6 wherein the linker does not comprise or consist of the sequence GGGGS.

A process for the manufacture of glycosylated p75NTR neurotrophin binding protein (NBP)-Fc fusion protein, comprising: a p75NTR(NBP) portion, having at least 85% sequence identitywith Seq ID No. 2; and an immunoglobulin Fc portion. wherein, the p75NTR(NBP) and Fc portions are connected via a linker, the linker comprises a peptide of formula Gx, where x is 1, 2, 3, 4, 5 or 6 wherein the linker does not comprise or consist of the sequence GGGGS, characterised by expression from CHO cells, wherein cells are harvested within earlier of 30 hours of cell culture viability reaching 75% or, 12 days post inoculation.

Disclosed is a method of reducing and / or removing diglyceride content in an oil without substantial transesterification of triglycerides, the method comprising the steps of: providing an oil or fat; and hydrolyzing the monoglycerides and diglycerides in the oil with water in the presence of a lipase having at least 80% sequence identity to SEQ ID NO: 1.

The present invention pertains to pharmaceutical compositions comprising protein oligomers for passive immunization and therapy. Specifically, the present invention relates to a pharmaceutical composition comprising a protein oligomer comprising at least a first and a second monomer, said at least first and second monomer comprising, in N- to C-terminal order, at least one first receptor binding domain (RBD), an immunoglobulin Fc (Ig Fc), and at least one second receptor binding domain (RBD), wherein a) Ig Fc has enhanced affinity for the neonatal Fc receptor (FcRn) at mucosal pH, compared to wildtype Ig Fc; and b) RBD is a receptor binding domain from or derived from SARS-CoV-2 spike protein, wherein the receptor binding domain comprises the amino acid sequence of SEQ ID NO. 13, or an amino acid sequence having at least 80%, 85%, 90%, or 95% sequence identity to SEQ ID NO. 13.

Variants having cutinase activity of a parent cutinase, the variants comprising alterations at one or more (e.g., several) positions corresponding to positions 181, 182, 115, 161, 1, 2, 43, 55, 79, or 5 of SEQ ID NO: 2, where the alterations are substitutions for positions 181, 115, 161, 43, 55, 79, and 5, and deletions for positions 1, 2, and 182, and where the variants have at least 75% but less than 100% sequence identity to a mature polypeptide of SEQ ID NO: 2. Polynucleotides encoding the variants; nucleic acid constructs, vectors, and host cells including the polynucleotides; as well as methods for obtaining the variants and methods for producing the variants. Comprising the variants, and methods for using the variants.

The present invention relates to immunoglobulin single variable domains (ISVDs) for the treatment of diseases by the enteral, e.g. oral, delivery. In particular, the present invention provides ISVDs comprising sequences with a high percentage of sequence identity to SEQ ID NO: 1 for such enteral administration. Such sequences were identified as extraordinarily stable in the gastrointestinal tract, which prevents their degradation and thereby allows them to exert a strong therapeutic effect.

The invention provides an isolated or engineered polynucleotide (10) comprising a coding sequence (12), wherein the coding sequence (12) encodes a protein (20), wherein an amino acid sequence of the protein (20) has at least 85% sequence identity with a reference amino acid sequence in a sequence alignment between the amino acid sequence and the reference amino acid sequence, wherein the reference amino acid sequence is selected from the group consisting of SEQ ID NO:8 11 14 1720, and wherein the protein (20) is a cannabinoid acid synthase (25).